ESC 365 - Does prior MRA use limit eligibility for sacubitril valsartan in a heart failure clinic? Insights from real world experience and implications for ESC and NICE guidelines

HFA Premium Access

Does prior MRA use limit eligibility for sacubitril valsartan in a heart failure clinic? Insights from real world experience and implications for ESC and NICE guidelines

Session: Poster Session 2 - Chronic Heart Failure – Treatment

Topic: Pharmacotherapy

Speaker: Doctor L. Myslivecek (Bristol, GB)

Event: Heart Failure 2018

Congress Presentation

Add to my library

About the speaker

Doctor Libor Myslivecek

Bristol Heart Institute, Bristol (United Kingdom of Great Britain & Northern Ireland)

0 follower

61 more presentations in this session

Real-world patterns of loop diuretics dose adjustment and association with outcomes in outpatients with chronic heart failure: observations from the ESC Heart Failure Long-Term Registry

Speaker: Doctor C. Kapelios (Athens, GR)

Acute kidney failure and hyperkalaemia in patients with chronic hearth failure treated with aldosterone antagonists- a risk-benefit network meta-analysis

Intermittent administration of levosimendan ambulatory in patients with advanced chronic heart failure: experience in our center.

Sildenafil for chronic heart failure : a meta-analysis

Speaker: Mrs C. Ariano (Naples, IT)

The dilemma of recurrent hyperkalaemia and use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: a European multi-national targeted chart review

Speaker: Professor P. Rossignol (Monaco, MC)

Access the full session

Poster Session 2 - Chronic Heart Failure – Treatment

Speakers: Doctor L. Myslivecek, Doctor C. Kapelios, Mrs C. Ariano, Professor P. Rossignol

About the event

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources